Goldman Sachs
CRVS icon

Goldman Sachs’s Corvus Pharmaceuticals CRVS Stock Holding History

Goldman Sachs’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$1.59M – 6122
2025
Q1 		$1.59M Hold
500,000
– – ﹤0.01% 4341
2024
Q4 		$2.67M Hold
500,000
– – ﹤0.01% 4039
2024
Q3 		$2.64M Buy
+500,000
New +$1.8M ﹤0.01% 3905

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs's CRVS Position: Q1 2026 in Review

Goldman Sachs increased its Corvus Pharmaceuticals (CRVS) stake by 178% in Q1 2026, buying an estimated $15.8M and bringing the position to 1,540,809 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Goldman Sachs first reported a position in CRVS in Q1 2016 and has held it in 33 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Goldman Sachs held 1,540,809 shares of Corvus Pharmaceuticals worth $22.5M as of Q1 2026.
  • Goldman Sachs bought 987,482 Corvus Pharmaceuticals shares in Q1 2026, an estimated $15.8M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2319 holding.
  • Goldman Sachs first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 33 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.